Regulatory Affairs Leader Builds Strong EB-1A Profile Through Strategic CMC Leadership

How We Approached It

VisaArchitect built a structured case that highlighted Aarav's sustained recognition, technical expertise, and major contributions to the field. Here's what we focused on:

Peer Review and Regulatory Leadership

Aarav served as a technical reviewer for regulatory journals and industry forums, evaluating CMC submissions and regulatory strategy content. His review work spanned respected platforms like the International CMC Strategy Forum, the Regulatory Affairs Professionals Society (RAPS) Annual Meeting, and the Global Regulatory Review Panel.

Making Original Contributions That Mattered

Aarav designed regulatory submission strategies that supported accelerated pathways for three first-in-class therapies, cutting timelines by an average of eight months. He developed a risk-based CMC assessment framework that was adopted across multiple organizations. He also led successful negotiations with both the FDA and EMA, securing critical manufacturing flexibility for complex biologics programs.

Publications and Speaking at Industry Events

Aarav wrote white papers on CMC strategy and expedited development pathways that were published in leading regulatory affairs journals. He was invited to speak at major conferences including the RAPS Regulatory Convergence Conference, the PDA Global Conference on Pharmaceutical Microbiology, and the CMC Strategy Forum East Coast. His presentations covered regulatory risk mitigation, global harmonization, and lifecycle management best practices.

Leading and Mentoring Others

Beyond his regulatory leadership in industry, Aarav helped develop other professionals through mentorship and training. He mentored eight regulatory professionals through RAPS mentorship programs and internal initiatives. He also trained cross-functional teams on CMC submission strategy, quality-by-design principles, and regulatory intelligence. This work strengthened regulatory capabilities and directly supported product approvals and lifecycle optimization.

Professional Recognition and Standing

Aarav held Senior Member status within RAPS, reflecting demonstrated leadership and peer recognition. He maintained active membership with the Drug Information Association (DIA) and the Parenteral Drug Association (PDA), contributing to working groups focused on regulatory science advancement and CMC harmonization.

High Compensation

His compensation placed him in the top 10% of regulatory affairs professionals in the pharmaceutical sector. This was supported through independent benchmarking data and performance-based pay tied to his strategic contributions in drug development programs.

We positioned Aarav as "a regulatory affairs leader recognized for advancing CMC strategy, accelerating global approvals, and protecting patient safety through expert regulatory decision-making that strengthens the U.S. biopharmaceutical ecosystem."

The final submission was a 340-page petition package supported by seven expert letters from senior regulatory executives, CMC subject matter experts, and pharmaceutical R&D leaders across North America and Europe.

The Outcome

Aarav received his EB-1A approval without a Request for Evidence within the standard USCIS timeline. The adjudicating officer cited his sustained recognition through peer review, speaking engagements, and professional leadership roles, along with strong documentation of original contributions in CMC strategy that accelerated timelines and enabled approvals of novel therapies.

His case has become a strong example of how regulatory affairs professionals can demonstrate extraordinary ability through strategic decision-making and field-critical contributions that drive innovation and protect patient safety.